clinical trial · NCT07230106
A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.·phase2·recruiting·n = 218
Prostate CancerHS-20093 for InjectionSHR3680 TabletAbiraterone TabletSHR2554 TabletEnzalutamide TabletDarotamine Capsule
brief summary
This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.
started
Dec 8, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2029
last updated
Mar 3, 2026
official title
A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol